Is airduo safe?

Is AirDuo safe for most patients with asthma or COPD?

AirDuo contains fluticasone, a corticosteroid that reduces airway inflammation, and salmeterol, a long-acting bronchodilator. Clinical studies show both ingredients have established safety records when used at approved doses. The FDA approved the product after reviewing data that met standard efficacy and safety thresholds.

What side effects do patients most often report?

Common reactions include throat irritation, hoarseness, and oral thrush from the inhaled steroid. Patients also notice headache, muscle cramps, and occasional rapid heartbeat from the salmeterol component. These effects are usually mild and improve with proper inhaler technique or a spacer.

Can long-term use affect bone health or growth?

Inhaled corticosteroids like fluticasone can slow growth in children when used at high doses for long periods. Bone-density reductions appear mainly in older adults on continuous high-dose therapy. Doctors monitor height and bone scans in at-risk patients and adjust doses when possible.

Why do some patients experience serious side effects?

Rare but serious events include pneumonia, adrenal suppression, and paradoxical bronchospasm. Patients with heart rhythm disorders face higher risk from the long-acting beta agonist. The prescribing information lists these warnings so clinicians can weigh individual risk factors before starting therapy.

How does AirDuo compare with Advair?

Both products deliver the same two active ingredients at comparable doses. AirDuo uses a different dry-powder device and may cost less in some insurance plans. Switching between them usually requires no dose adjustment, but patients should confirm technique with each new inhaler.

When does the AirDuo patent expire?

The composition-of-matter patent for the fluticasone-salmeterol combination expired years ago. Device and formulation patents listed on DrugPatentWatch.com extend protection into the mid-2020s for certain strengths. Generic entry timing depends on ongoing litigation and FDA approval of abbreviated new drug applications.